BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl. 2001;7:701-708. [PMID: 11510015 DOI: 10.1053/jlts.2001.26510] [Cited by in Crossref: 123] [Cited by in F6Publishing: 99] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
2 Schubert M, Venkataramanan R, Holt DW, Shaw LM, Mcghee W, Reyes J, Webber S, Sindhi R. Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant Patients. Am J Transplant 2004;4:767-73. [DOI: 10.1111/j.1600-6143.2004.00411.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
3 Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91. [PMID: 17335296 DOI: 10.2165/00003495-200767030-00004] [Cited by in Crossref: 152] [Cited by in F6Publishing: 122] [Article Influence: 10.9] [Reference Citation Analysis]
4 Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, Levi DM, Tzakis AG, O'brien CB. Sirolimus-Associated Hepatotoxicity in Liver Transplantation. Ann Pharmacother 2004;38:1593-6. [DOI: 10.1345/aph.1e165] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
5 Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl. 2005;11:267-280. [PMID: 15719409 DOI: 10.1002/lt.20373] [Cited by in Crossref: 70] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
6 Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, Genyk Y, Mateo R, Gagandeep S, Sher LS. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther. 2006;23:513-520. [PMID: 16441472 DOI: 10.1111/j.1365-2036.2006.02770.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
7 Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother 2007;8:1275-82. [PMID: 17563262 DOI: 10.1517/14656566.8.9.1275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Spada M, Riva S, Maggiore G, Cintorino D, Gridelli B. Pediatric liver transplantation. World J Gastroenterol. 2009;15:648-674. [PMID: 19222089 DOI: 10.3748/wjg.15.648] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
9 Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant. 2009;2009:701464. [PMID: 20130772 DOI: 10.1155/2009/701464] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
10 Hu AB, Wu LW, Tai Q, Zhu XF, He XS. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center: Steroid-minimization in LT. Journal of Digestive Diseases 2013;14:38-44. [DOI: 10.1111/1751-2980.12008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
11 Wall WJ. Hepatocellular cancer, transplantation, and sirolimus. Liver Transpl 2004;10:1312-4. [DOI: 10.1002/lt.20283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
12 Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35:193S-200S. [PMID: 12742496 DOI: 10.1016/S0041-1345(03)00234-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 15] [Article Influence: 5.1] [Reference Citation Analysis]
13 El-sabrout R, Delaney V, Qadir M, Butt F, Hanson P, Butt K. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients—a single center experience. Transplantation Proceedings 2003;35:S89-94. [DOI: 10.1016/s0041-1345(03)00220-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008;14:633-638. [PMID: 18324656 DOI: 10.1002/lt.21420] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 11.4] [Reference Citation Analysis]
15 Mehra MR, Uber PA. TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? The Journal of Heart and Lung Transplantation 2003;22:501-4. [DOI: 10.1016/s1053-2498(02)00525-9] [Cited by in Crossref: 16] [Article Influence: 0.9] [Reference Citation Analysis]
16 Lo A, Egidi MF, Gaber LW, Shokouh-Amiri MH, Nazakatgoo N, Fisher JS, Gaber AO. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 2004;18:53-61. [PMID: 15108771 DOI: 10.1111/j.1399-0012.2004.00116.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
17 Markiewicz M, Kalicinski P, Teisseyre J, Ismail H, Kaminski A, Teisseyre M. Rapamycin in children after liver transplantation. Transplantation Proceedings 2003;35:2284-6. [DOI: 10.1016/s0041-1345(03)00785-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
18 Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I. A Decade of Experience Using mTor Inhibitors in Liver Transplantation. J Transplant. 2011;2011:913094. [PMID: 21461386 DOI: 10.1155/2011/913094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
19 Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol. 2009;15:4225-4233. [PMID: 19750565 DOI: 10.3748/wjg.15.4225] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
20 Firpi RJ, Tran TT, Flores P, Nissen N, Colquhoun S, Shackleton C, Martin P, Vierling JM, Poordad FF. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther. 2004;19:1033-1039. [PMID: 15113371 DOI: 10.1111/j.1365-2036.2004.01923.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
21 Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56:23-46. [PMID: 16039869 DOI: 10.1016/j.critrevonc.2005.03.012] [Cited by in Crossref: 271] [Cited by in F6Publishing: 215] [Article Influence: 16.9] [Reference Citation Analysis]
22 Jain A. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: A case report. Liver Transplantation 2002;8:838-40. [DOI: 10.1053/jlts.2002.34921] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
23 Furukawa H, Todo S. Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. Transplantation Proceedings 2004;36:S274-84. [DOI: 10.1016/j.transproceed.2004.01.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
24 Alemdar AY, Sadi D, McAlister V, Mendez I. Intracerebral co-transplantation of liposomal tacrolimus improves xenograft survival and reduces graft rejection in the hemiparkinsonian rat. Neuroscience 2007;146:213-24. [PMID: 17303340 DOI: 10.1016/j.neuroscience.2007.01.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
25 Shah M, Shankar A, Gee I, Nash K, Hoare M, Gibbs P, Davies S, Alexander GJM. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients. Aliment Pharmacol Ther 2015;41:379-92. [DOI: 10.1111/apt.13049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Pascual J, Royuela A, Fernández AM, Herrero I, Delgado JF, Solé A, Guirado L, Serrano T, de la Torre-Cisneros J, Moreno A, Cordero E, Gallego R, Lumbreras C, Aguado JM; Spanish Society of Transplantation Virological and Immune Response Investigation Study Group. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis 2016;18:819-31. [PMID: 27600985 DOI: 10.1111/tid.12601] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
27 El-sabrout R, Delaney V, Butt F, Qadir M, Hanson P, Tuteja S, Mccollum DA, Butt K. Improved freedom from rejection after a loading dose of sirolimus: . Transplantation 2003;75:86-90. [DOI: 10.1097/00007890-200301150-00016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
28 Kelly D. Long-Term Challenges of Immunosuppression in Pediatric Patients. Transplantation Proceedings 2005;37:1657-62. [DOI: 10.1016/j.transproceed.2005.02.105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 2001;7:S60-S73. [PMID: 11689778 DOI: 10.1053/jlts.2001.29094] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
30 Liu LU, Schiano TD. Long-term care of the liver transplant recipient. Clin Liver Dis. 2007;11:397-416. [PMID: 17606214 DOI: 10.1016/j.cld.2007.04.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
31 Fridell JA, Jain AKB, Patel K, Virji M, Rao KN, Fung JJ, Venkataramanan R. Phenytoin Decreases the Blood Concentrations of Sirolimus in a Liver Transplant Recipient: A Case Report: . Therapeutic Drug Monitoring 2003;25:117-9. [DOI: 10.1097/00007691-200302000-00019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
32 Senzolo M, Ferronato C, Burra P. Neurologic complications after solid organ transplantation. Transpl Int. 2009;22:269-278. [PMID: 19076332 DOI: 10.1111/j.1432-2277.2008.00780.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 71] [Article Influence: 9.0] [Reference Citation Analysis]
33 Streit F, Armstrong VW, Oellerich M. Rapid Liquid Chromatography–Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Sirolimus, Everolimus, Tacrolimus, and Cyclosporin A in Whole Blood. Clinical Chemistry 2002;48:955-8. [DOI: 10.1093/clinchem/48.6.955] [Cited by in Crossref: 154] [Cited by in F6Publishing: 116] [Article Influence: 8.1] [Reference Citation Analysis]
34 Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P. Minimization of steroids in liver transplantation. Transpl Int 2009;22:2-19. [PMID: 19121145 DOI: 10.1111/j.1432-2277.2008.00758.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
35 McDiarmid SV. Current status of liver transplantation in children. Pediatr Clin North Am. 2003;50:1335-1374. [PMID: 14710783 DOI: 10.1016/S0031-3955(03)00150-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
36 Sofroniadou S, Goldsmith D. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf. 2011;34:97-115. [PMID: 21247219 DOI: 10.2165/11585040] [Reference Citation Analysis]
37 Watson CJ, Bradley JA. Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transplantation Reviews 2006;20:104-14. [DOI: 10.1016/j.trre.2006.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
38 Pham S, Qi X, Mallon S, Kaplon R, Bauerlein E, Katariya K, Sequeira R, Bolooki H, Rosenkranz E, Loo A, Lee P, Jimenez J, Salerno T. Sirolimus and tacrolimus in clinical cardiac transplantation. Transplantation Proceedings 2002;34:1839-42. [DOI: 10.1016/s0041-1345(02)03098-1] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
39 Everson GT. Everolimus and mTOR inhibitors in liver transplantation: Opening the “box”. Liver Transpl 2006;12:1571-3. [DOI: 10.1002/lt.20845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
40 Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006;20 Suppl 17:30-43. [PMID: 17100699 DOI: 10.1111/j.1399-0012.2006.00598.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
41 MacDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 2003;35:201S-8S. [PMID: 12742497 DOI: 10.1016/s0041-1345(03)00231-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
42 Vilatoba M, Contreras JL, Eckhoff DE. New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity: . Current Opinion in Organ Transplantation 2003;8:139-45. [DOI: 10.1097/00075200-200306000-00002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Birnbaum F, Reis A, Böhringer D, Sokolowska Y, Mayer K, Voiculescu A, Oellerich M, Sundmacher R, Reinhard T. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 2006;81:767-72. [PMID: 16534481 DOI: 10.1097/01.tp.0000191291.71003.1b] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
44 Scherer MN, Banas B, Mantouvalou K, Schnitzbauer A, Obed A, Krämer BK, Schlitt HJ. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg 2007;392:511-23. [DOI: 10.1007/s00423-007-0188-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
45 Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83:1162-1168. [PMID: 17496530 DOI: 10.1097/01.tp.0000262607.95372.e0] [Cited by in Crossref: 137] [Cited by in F6Publishing: 113] [Article Influence: 9.8] [Reference Citation Analysis]
46 Fung J. Rapamycin: Friend, foe, or misunderstood? Liver Transplantation 2003;9:469-72. [DOI: 10.1053/jlts.2003.50101] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
47 Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22:1-15. [PMID: 18217899 DOI: 10.1111/j.1399-0012.2007.00739.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 48] [Article Influence: 0.8] [Reference Citation Analysis]
48 Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl. 2007;13:1694-1702. [PMID: 18044728 DOI: 10.1002/lt.21314] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
49 Groetzner J, Meiser B, Landwehr P, Buehse L, Mueller M, Kaczmarek I, Vogeser M, Daebritz S, Ueberfuhr P, Reichart B. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure: . Transplantation 2004;77:568-74. [DOI: 10.1097/01.tp.0000103740.98095.14] [Cited by in Crossref: 104] [Cited by in F6Publishing: 6] [Article Influence: 6.1] [Reference Citation Analysis]
50 Guarino M, Benito-Leon J, Decruyenaere J, Schmutzhard E, Weissenborn K, Stracciari A. EFNS guidelines on management of neurological problems in liver transplantation. Eur J Neurol. 2006;13:2-9. [PMID: 16420387 DOI: 10.1111/j.1468-1331.2006.01353.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
51 Sofroniadou S, Goldsmith D. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 2011;34:97-115. [PMID: 21247219 DOI: 10.2165/11585040-000000000-00000] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
52 Groetzner J, Kur F, Spelsberg F, Behr J, Frey L, Bittmann I, Vogeser M, Ueberfuhr P, Meiser B, Hatz R. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant. 2004;23:632-638. [PMID: 15135383 DOI: 10.1016/s1053-2498(03)00309-7] [Cited by in Crossref: 113] [Cited by in F6Publishing: 16] [Article Influence: 6.6] [Reference Citation Analysis]
53 Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol 2006;12:3114-8. [PMID: 16718799 DOI: 10.3748/wjg.v12.i19.3114] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
54 Kelly DA. Strategies for Optimizing Immunosuppression in Adolescent Transplant Recipients: A Focus on Liver Transplantation. Pediatric Drugs 2003;5:177-83. [DOI: 10.2165/00128072-200305030-00004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
55 Lo A, Egidi MF, Gaber LW, Gaber AO. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. Transplant Proc 2003;35:105S-8S. [PMID: 12742477 DOI: 10.1016/s0041-1345(03)00238-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
56 Lisik W, Kahan BD. Proliferation signal inhibitors: chemical, biologic, and clinical properties. Transplantation Reviews 2005;19:186-212. [DOI: 10.1016/j.trre.2005.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
57 Mukherjee S, Botha JF, Mukherjee U. Immunosuppression in liver transplantation. Curr Drug Targets. 2009;10:557-574. [PMID: 19519358 DOI: 10.1002/lt.20614] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
58 Al-hussaini A, Tredger JM, Dhawan A. Immunosuppression in Pediatric Liver and Intestinal Transplantation: A Closer Look at the Arsenal: . Journal of Pediatric Gastroenterology and Nutrition 2005;41:152-65. [DOI: 10.1097/01.mpg.0000172260.46986.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
59 Kong Y, Wang D, Shang Y, Liang W, Ling X, Guo Z, He X. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One. 2011;6:e24387. [PMID: 21931704 DOI: 10.1371/journal.pone.0024387] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
60 Ferreiro AO, Vazquez-Millán MA, López FS, Gutiérrez MG, Diaz SP, Patiño MJ. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series. Transplant Proc 2014;46:3496-501. [PMID: 25498079 DOI: 10.1016/j.transproceed.2014.08.045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
61 Pleguezuelo M, Germani G, Burroughs AK. Liver Transplantation: Prevention and Treatment of Rejection. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 685-723. [DOI: 10.1002/9781444314403.ch42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
62 Sanchez Antolín G, Garcia Pajares F, Lorenzo Pelayo S, Herranz Bachiller MT, Almohalla C, Velicia R, Caro Paton A. Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. Transplant Proc. 2011;43:714-717. [PMID: 21486581 DOI: 10.1016/j.transproceed.2011.01.105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
63 Schumacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR, Rueggeberg A, Neuhaus R, Bahra M, Jacob D. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc. 2002;34:1392-1393. [PMID: 12176410 DOI: 10.1016/s0041-1345(02)02899-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
64 Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc. 2003;35:209S-216S. [PMID: 12742498 DOI: 10.1016/s0041-1345(03)00217-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
65 Campagna F, Biancardi A, Cillo U, Gatta A, Amodio P. Neurocognitive-neurological complications of liver transplantation: a review. Metab Brain Dis. 2010;25:115-124. [PMID: 20204483 DOI: 10.1007/s11011-010-9183-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
66 Fisher A, Seguel JM, de la Torre AN, Wilson D, Merchant A, Arora RK, Koneru B. Effect of sirolimus on infection incidence in liver transplant recipients: Sirolimus in Liver Transplantation. Liver Transpl 2004;10:193-8. [DOI: 10.1002/lt.20072] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
67 de Mare-Bredemeijer EL, Metselaar HJ. Optimization of the use of Calcineurin inhibitors in liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26:85-95. [PMID: 22482528 DOI: 10.1016/j.bpg.2012.01.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
68 Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. Pediatric Transplantation 2005;9:269-76. [DOI: 10.1111/j.1399-3046.2005.00305.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
69 Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 2003;9:463-468. [PMID: 12740787 DOI: 10.1053/jlts.2003.50079] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
70 Mckenna GJ, Trotter JF. Sirolimus – It doesn’t deserve its bad Rap(a). Journal of Hepatology 2012;56:285-7. [DOI: 10.1016/j.jhep.2011.06.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
71 Mehrabi A, Fonouni H, Wente M, Sadeghi M, Eisenbach C, Encke J, Schmied BM, Libicher M, Zeier M, Weitz J. Wound complications following kidney and liver transplantation. Clin Transplant. 2006;20 Suppl 17:97-110. [PMID: 17100709 DOI: 10.1111/j.1399-0012.2006.00608.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 82] [Article Influence: 8.2] [Reference Citation Analysis]
72 Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, Krom RA. Recent advances in liver transplantation. Mayo Clin Proc. 2003;78:197-210. [PMID: 12583530 DOI: 10.4065/78.2.197] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
73 Iglesias J, Ortega J, Lopez JA, Sanchez L, Allende E, Asensio M, Margarit C. Rapamycin-based rescue therapy after chronic rejection in a pediatric liver transplant patient. Transplant Int 2003;16:765-7. [DOI: 10.1111/j.1432-2277.2003.tb00238.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
74 Jain A, Sharma R, Ryan C, Tsoulfas G, Orloff M, Abt P, Kashyap R, Batzold P, Sauberman L, Safadjou S. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction. Liver Transpl. 2008;14:202-209. [PMID: 18236395 DOI: 10.1002/lt.21348] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
75 Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, Bahra M, Neuhaus P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol. 2005;11:1420-1425. [PMID: 15770715 DOI: 10.3748/wjg.v11.i10.1420] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
76 Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, Guarrera JV, Brown RS Jr. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplantation 2011;91:1254-60. [PMID: 21617588 DOI: 10.1097/TP.0b013e318218f0f5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
77 Chueh SC, Kahan BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int. 2005;18:261-277. [PMID: 15730485 DOI: 10.1111/j.1432-2277.2004.00039.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
78 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485. [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006] [Cited by in Crossref: 390] [Cited by in F6Publishing: 254] [Article Influence: 65.0] [Reference Citation Analysis]
79 Salm P, Taylor PJ, Rooney F. A High-Performance Liquid Chromatography-Mass Spectrometry Method Using a Novel Atmospheric Pressure Chemical Ionization Approach for the Rapid Simultaneous Measurement of Tacrolimus and Cyclosporin in Whole Blood. Therapeutic Drug Monitoring 2008;30:292-300. [DOI: 10.1097/ftd.0b013e3181771feb] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
80 Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation 2011;91:128-32. [PMID: 21452417 DOI: 10.1097/tp.0b013e3181fe131b] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
81 Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Shiffman ML, Posner MP. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002;16 Suppl 7:49-51. [PMID: 12372044 DOI: 10.1034/j.1399-0012.16.s7.7.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
82 Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, Nashan B, Peltekian KM. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007;13:1109-1114. [PMID: 17663411 DOI: 10.1002/lt.21126] [Cited by in Crossref: 217] [Cited by in F6Publishing: 161] [Article Influence: 15.5] [Reference Citation Analysis]
83 Calmus Y, Durrbach A. Everolimus de novo in liver transplantation. Gastroenterol Clin Biol. 2009;33 Suppl 4:S247-S252. [PMID: 20004330 DOI: 10.1016/s0399-8320(09)73161-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
84 Molinari M, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010;23:155-168. [PMID: 19765266 DOI: 10.1111/j.1432-2277.2009.00969.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
85 Kelly DA. Current issues in pediatric transplantation. Pediatr Transplant. 2006;10:712-720. [PMID: 16911496 DOI: 10.1111/j.1399-3046.2006.00567.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
86 Ferede AA, O'Connell C, Davis NF, Mohan P, Robertson I, O'Kelly P, Little DM. The Irish experience of kidney transplantation among recipients with prior non-renal solid organ transplants: A retrospective study on short- and long-term outcomes. Clin Transplant 2021;35:e14156. [PMID: 33222237 DOI: 10.1111/ctr.14156] [Reference Citation Analysis]
87 Avitzur Y, Jimenez-rivera C, Fecteau A, Jones N, Ngan BY, Ng VL. Interstitial Granulomatous Pneumonitis associated with Sirolimus in a Child after Liver Transplantation: . Journal of Pediatric Gastroenterology and Nutrition 2003;37:91-4. [DOI: 10.1097/00005176-200307000-00017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
88 Liu YX, Jin LM, Zhou L, Xie HY, Jiang GP, Chen H, Zheng SS. Sirolimus attenuates reduced-size liver ischemia-reperfusion injury but impairs liver regeneration in rats. Dig Dis Sci. 2010;55:2255-2262. [PMID: 19856103 DOI: 10.1007/s10620-009-1002-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
89 Choudhary NS, Saigal S, Shukla R, Kotecha H, Saraf N, Soin AS. Current status of immunosuppression in liver transplantation. J Clin Exp Hepatol 2013;3:150-8. [PMID: 25755489 DOI: 10.1016/j.jceh.2013.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
90 Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425-4431. [PMID: 18776081 DOI: 10.1182/blood-2008-07-169342] [Cited by in Crossref: 111] [Cited by in F6Publishing: 86] [Article Influence: 8.5] [Reference Citation Analysis]
91 Moser MA. Options for Induction Immunosuppression in Liver Transplant Recipients: . Drugs 2002;62:995-1011. [DOI: 10.2165/00003495-200262070-00002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
92 Fasola CG, Klintmalm GB. Impact of immunosuppression in hepatitis C recurrence after liver transplantation: a controllable factor?: . Current Opinion in Organ Transplantation 2003;8:146-52. [DOI: 10.1097/00075200-200306000-00003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
93 Cabezón S, Lage E, Hinojosa R, Ordóñez A, Campos A. Sirolimus Improves Renal Function in Cardiac Transplantation. Transplantation Proceedings 2005;37:1546-7. [DOI: 10.1016/j.transproceed.2005.02.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
94 Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J Hepatol 2012;56:288-90. [PMID: 21741926 DOI: 10.1016/j.jhep.2011.06.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
95 Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18:62-69. [PMID: 21964956 DOI: 10.1002/lt.22441] [Cited by in Crossref: 109] [Cited by in F6Publishing: 89] [Article Influence: 12.1] [Reference Citation Analysis]
96 Ferrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol 2006;149:133-5. [PMID: 16894342 DOI: 10.1038/sj.bjp.0706860] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
97 Toso C, Patel S, Asthana S, Kawahara T, Girgis S, Kneteman NN, Shapiro AM, Bigam DL. The impact of sirolimus on hepatocyte proliferation after living donor liver transplantation. Clin Transplant. 2010;24:695-700. [PMID: 20002466 DOI: 10.1111/j.1399-0012.2009.01159.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
98 Washburn K. Endpoints in trials for clinical liver transplantation. Current Opinion in Organ Transplantation 2008;13:252-6. [DOI: 10.1097/mot.0b013e3282ff84b2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Raimondo ML, Burroughs AK. Single-Agent Immunosuppression After Liver Transplantation: What is Possible? Drugs 2002;62:1587-97. [DOI: 10.2165/00003495-200262110-00002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]